Chicago Partners Investment Group LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,300 shares of the company’s stock after selling 44 shares during the period. Chicago Partners Investment Group LLC’s holdings in Eli Lilly and were worth $193,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. Joel Isaacson & Co. LLC raised its stake in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after buying an additional 50 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock worth $27,280,000 after buying an additional 9,680 shares during the last quarter. Washington Trust Bank raised its stake in Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock worth $872,000 after buying an additional 4,990 shares during the last quarter. Bollard Group LLC raised its stake in Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock worth $26,408,000 after buying an additional 8,153 shares during the last quarter. Finally, Sabal Trust CO raised its stake in Eli Lilly and by 1.2% in the first quarter. Sabal Trust CO now owns 6,400 shares of the company’s stock worth $538,000 after buying an additional 75 shares during the last quarter. Institutional investors and hedge funds own 75.48% of the company’s stock.

Eli Lilly and Company (LLY) opened at 82.31 on Friday. The firm’s 50-day moving average is $82.99 and its 200 day moving average is $81.53. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The stock has a market capitalization of $86.84 billion, a P/E ratio of 35.62 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the prior year, the company posted $0.86 EPS. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities analysts expect that Eli Lilly and Company will post $4.16 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

TRADEMARK VIOLATION WARNING: “Eli Lilly and Company (LLY) Position Cut by Chicago Partners Investment Group LLC” was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/05/eli-lilly-and-company-lly-position-cut-by-chicago-partners-investment-group-llc.html.

LLY has been the topic of a number of research reports. BMO Capital Markets set a $71.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, April 25th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a research note on Monday, July 17th. Credit Suisse Group reiterated an “outperform” rating and issued a $87.00 price objective on shares of Eli Lilly and in a research note on Wednesday, April 19th. Barclays PLC increased their price objective on shares of Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, April 7th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $92.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a research note on Saturday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and a consensus price target of $88.27.

In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the transaction, the insider now directly owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 669,733 shares of company stock worth $55,845,287. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.